Business Context and Reporting Period
Company: CURIS, INC.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Overview: Curis is a drug discovery and development company focused on targeted cancer therapies. Its primary revenue source is strategic collaborations, most notably with Genentech regarding the Hedgehog pathway inhibitor GDC-0449. The company also pursues internal development of proprietary targeted cancer programs, including CUDC-101 (Phase I) and CUDC-305 (preclinical).
Key Financial Metrics
| Metric (in thousands) | 2008 | 2007 |
|---|---|---|
| Net Revenues | $8,367 | $16,389 |
| Research & Development Expenses | $13,226 | $14,779 |
| General & Administrative Expenses | $8,260 | $9,984 |
| Net Loss | $(12,123) | $(6,964) |
| Cash, Cash Equivalents & Marketable Securities | $28,853 | $41,459 |
| Working Capital | $26,748 | $35,410 |
| Accumulated Deficit | $(707,971) | $(695,848) |
Revenue Composition (2008): Genentech accounted for 75% ($6.28M) and Stryker Corporation accounted for 21% ($1.75M) of total revenue.
Material Changes vs. Prior Period
- Revenue Decline: Net revenues decreased 49% to $8.37 million from $16.39 million in 2007. This was primarily due to the conclusion of research funding under various collaborations and the recognition of $7.5 million in previously deferred revenue in 2007 related to the Genentech collaboration.
- Expense Reductions: R&D expenses decreased 11% and G&A expenses decreased 17% due to cost-cutting measures implemented in October 2008, including reductions in personnel, legal, and occupancy costs.
- Increased Loss: Despite lower expenses, the net loss widened to $12.1 million from $7.0 million, driven by the significant drop in revenue.
- Asset Base: Cash and marketable securities decreased by approximately $12.6 million, reflecting the net cash used in operating activities of $12.4 million.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management anticipates that existing capital resources ($28.9 million) combined with a $6.0 million milestone payment expected from Genentech in Q1 2009 (triggered by the initiation of a pivotal Phase II trial for GDC-0449) will fund operations into mid-2010. The company expects to incur substantial operating losses for the foreseeable future.
Key Drivers:
- Success of Genentech's clinical trials for GDC-0449.
- Ability to secure a collaboration for internal candidates CUDC-101 or CUDC-305.
- Progress of the Phase I trial for CUDC-101.
Risks and Contingencies:
- Financing Risk: The company requires substantial additional capital to continue operations beyond mid-2010. Failure to secure funding could force the curtailment of development programs.
- Collaboration Dependence: Future revenue is heavily dependent on Genentech's discretion and success in developing GDC-0449. Genentech may terminate the agreement or deprioritize the program.
- Development Risk: All drug candidates are in early stages; clinical trials may fail, or regulatory approval may not be obtained.
- Market Conditions: Volatile credit and equity markets may make raising capital more difficult or dilutive.
Investor Verification Checklist
- Genentech Milestone Payment: Verify the receipt of the $6.0 million payment in Q1 2009 and its impact on cash flow.
- Cash Runway: Confirm the company's ability to fund operations through mid-2010 given the current burn rate and lack of new revenue streams.
- Collaboration Status: Monitor Genentech's progress in the pivotal Phase II trial for GDC-0449 in basal cell carcinoma and the status of Roche's involvement in non-U.S. markets.
- Internal Pipeline: Track the enrollment and safety data of the CUDC-101 Phase I trial and the IND filing timeline for CUDC-305.
- Capital Markets: Assess the feasibility of raising additional equity or debt financing in the current economic environment.